首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 201 毫秒
1.
Background No efficient therapy for liver fibrosis has been available. This study was aimed to provide evidence that the introduction of a plasmid expressing antisense tissue inhibitor of metalloproteinase-1 (TIMP-1) into a rat model of immunologically induced liver fibrosis can result in the increased activity of interstitial collagenase, thus enhancing the degradation of collagen.Methods Real-time nested polymerase chain reaction (RT-Nested-PCR) and gene recombination techniques were used to construct a rat antisense TIMP-1 recombinant plasmid that can be expressed in eukaryotic cells. Both the recombinant plasmid and an empty vector (pcDNA3) were encapsulated with glycosyl-poly-L-lysine and injected into rats suffering from pig serum-induced liver fibrosis. The expression of exogenous transfected plasmid was assessed by Northern blot, RT-PCR, and Western blot. Hepatic interstitial collagenase activity was detected using fluorescinisothiocyanate (FITC)-labeled type Ⅰ collagen. In addition to hepatic hydroxyproline content, hepatic collagen types Ⅰ and Ⅲ were detected by immunohistochemical staining, and the stages of liver fibrosis by Van Gieson staining.Results Exogenous antisense TIMP-1 was successfully expressed in vivo and could block the gene and protein expression of TIMP-1. Active and latent hepatic interstitial collagenase activities were elevated (P<0.01), hepatic hydroxyproline content and the accumulation of collagen types Ⅰ and Ⅲ were lowered, and liver fibrosis was alleviated in the antisense TIMP-1 group (P<0.01) as compared with the model group. Conclusion The results demonstrate that antisense TIMP-1 recombinant plasmids have some inhibitory effect on liver fibrosis.  相似文献   

2.
Objective:To construct and identify a vector expressing TRAM siRNA in mammalian cells.Methods :It was constructed that the vector named R-pSUPER-EGFP used to transcribe functional TRAM siRNA. Two of pair 64 nt TRAM gene specific target sequences were inserted into the downstream of the H1 promoter. The recombinants were transformed into E. coli JM109, and finally their veracity was confirmed by double cutting with the enzymes and sequencing. R-pSUPER-EGFP was transfected into RAW264. 7 cell by using LipofectamineTM2000, and the expression of TRAM was detected by Western blotting. Results .. Two different recombinant plasmids containing corresponding TRAM gene specific target sequences were constructed, transfected into RAW264.7 cell line successively, which can specifically restrain expression of TRAM protein. Conclusion :The optimizing method in constructing the recombinant vector serves other plasmid-based RNA interference research. Therefore, the recombinant vectors establish the basis for research on the function of TRAM gene.  相似文献   

3.
A new type of TGF-β3 fusion protein with targeted therapy function was constructed,and its feasibility and target specificity of inducing chondrogenesis were investigated by transfecting LAP-MMP-mTGF-β3 gene into adipose-derived stem cells (ADSCs).The recombinant pIRESEGFP-MMP was constructed by inserting the sense and antisense DNA of encoding the amino acid of the synthetic MMP enzyme cutting site into the eukaryotic expression vector pIRES-EGFP.LAP and mTGF-β3 fragments were obtained by using RT-PCR and inserted into the upstream and downstream of MMP from pIRES-EGFP-MMP respectively,and the recombinant plasmid of pIRES-EGFPLAP-MMP-mTGF-β3 was constructed,which was transferred to ADSCs.The ADSCs were cultured and divided in three groups:experimental group (MMP group),negative control group (no MMP) and non-transfection group.The morphological changes were observed microscopically,and the expression of proteoglycan and type Ⅱ collagen (ColⅡ) was detected by using Alcian blue staining and immunohistochemistry staining at 7th,14th and 21st day after culture.The recombinant plasmid of pIRES-EGFP-LAP-MMP-mTGF-β3 was correctly constructed by methods of enzyme cutting and sequencing analysis.The mTGF-β3 fusion protein was successfully expressed after transfection,and in the presence of the MMP,active protein mTGF-β3 was generated,which significantly promoted differentiation of ADSCs into chondrocytes and the expression of cartilage matrix.The novel fusion protein LAP-MMP-mTGF-β3 can targetedly induce differentiation of ADSCs into chondrocytes,which would open up prospects for target therapy of cartilage damage repair in future.  相似文献   

4.
The bFGF plays an important role in embryonic development of tendons and ligaments and in the healing of injuried tendons and ligaments. The eukaryotic expression plasmid of rat basic fibroblast growth factor (bFGF) gene was constructed in order to further investigate the bFGF func-tion in molecular regulatory mechanism in the repair of tendons and ligaments and to provide the foundation for the clinical application. The cDNA fragments of bFGF were cloned from the skin of rats by RT-PCR, and recombinated to the pMD18-T vector. The cDNA encoding bFGF was cloned from the pMD18-T vector by RT-PCR, digested with restriction enzyme EcoRⅠ, PstⅠ and bound to eukaryotic expression plasmid pIRES2-EGFP to construct eukaryotic expression plasmid pIRES2-EGFP-bFGF. The pIRES2-EGFP-bFGF was transfected into the tenocytes by lipid-mediated ransfection technique. MTT test was used to detect the biological activity of bFGF in supernatants after the transfection. The expression of type Ⅰ and Ⅲ collagen genes was detected by using RT-PCR. It was verified that the pIRES2-EGFP-bFGF was successfully constructed, and its transfec-tion into tenocytes could significantly enhance the biological activity of bFGF, and increase the ex-pression of type Ⅰ and Ⅲ collagen mRNA, suggesting that pIRES2-EGFP-mediated bFGF gene therapy was beneficial to the repair of tendons and ligaments.  相似文献   

5.
Objective To construct vectors expressing siRNA against human ER-β gene and study the inhibition effect of ER-β-siRNA on expression of ER-β in human periodontal ligament (HPDL) cells. Methods ER-β-specific siRNA gene was synthesized and cloned into pSilencer3.1-Hl-neo vector. The plasmid was identified by DNA sequencing. The constructed ER-β-siRNA was transfected into HPDL cells. The expression of ER-β in the levels of mRNA was detected by RT-PCR. Results It was confirmed by sequencing that the plasmid had been constructed successfully. The result of RT-PCR showed that Sequence-specific siRNAs targeting ER-β significantly down regulated the expression of ER-β gene in HPDL cells. Conclusion The ER-β siRNA plasmid was constructed successfully. ER-β gene expression of HPDL cells was inhibited by RNAi.  相似文献   

6.
Background Ischemic disease is one of the leading causes of death in the world. In order to further study gene therapy for ischemic disease, we constructed a recombinant plasmid for co-expression of human angiopoietin-1 and vascular endothelial growth factor 165 (VEGF165) gene in adeno-associated virus (AAV) gene delivery system.Methods Human angiopoietin 1 and VEGF165 gene were obtained using PCR. The upstream of angiopoietin 1 contained restriction enzyme site Hind Ⅲ,contained restriction enzyme site BamH Ⅰ. The upstreamand the downstream of angiopoietin 1 of VEGF165 contained restriction enzyme site Bgl Ⅱ, and the downstream of VEGF165 contained restriction enzyme site BamH Ⅰ, Using the multiple cloning sites (MCS) in plasmid pZero such as BamH Ⅰ , Bgl Ⅱ, Hind Ⅲ, Not Ⅰ , Xho Ⅰ ,Xba Ⅰ , Sal Ⅰ , BspH Ⅰ , Ksp Ⅰ and the corresponding MCS in plasmid pAAV-MCS, angiopoietin 1 and VEGF165 gene were subcloned into pAAV-MCS.Results DNA sequencing revealed that the PCR- amplified angiopoietin 1 and VEGF165 were consistent with NCBI Gene Bank. The recombinant plasmid was identified using PCR and digestion,which proved to be consistent with our hypothesis. In recombinant plasmid, angiopoietinl and VEGF possessed a CMV promoter and polyA terminator system respectively, thus assuring co-expression of the two genes.Conclusion Successful construction of AAV co-expression system for human angiopoietin 1 and VEGF165 gene will provide the foundation for gene therapy to cure severe ischemic disease.  相似文献   

7.
To construct a pUCP18/lasRantisense plasmid carrying the reversed gene and analyze its effect on the virulence of Pseudomonas aeruginosus,LasR gene was amplified from the genome of Pseudomonas aeruginosus by PCR and reversely recombined with plasmid pUCP18.The recombi-nant pUCP18/lasRantisense was verified by enzyme digestion,PCR and sequencing.The biological ef-fects of pUCP18/lasRantisense were examined by using RT-PCR,NAD method and the assay of pyo-cyanin.Our results showed that the expected full length lasR fragment(721 bp) was extended from Pseudomonas aeruginosus gene with PCR.And it is consistent with LasR gene of Pseudomonas aeruginosa in GenBank(No.NC-002516).The recombinant plasmid was successfully constructed and transferred into Pseudomonas aeruginosus.The antisense nucleic acid of LasR gene could reduce the virulence of Pseudomonas aeruginosus and might serve as a new target site for treatment purpose.  相似文献   

8.
9.
10.
In gene therapy for any type of malignancy, tumor specificity is of utmost importance. Here we constructed the adenoviral vector bringing EGFP gene under the control of survivin promoter for evaluation of the possibility of target gene therapy in laryngeal carcinoma. First, Survivin promoter (SP) was amplified by PCR in the replace of CMV promoter in the plasmid pShuttle. Enhanced green fluorescent protein gene (EGFP) digested from the plasmid pEGFP-CI was cloned into plasmid pShuttle. Further two genes were cloned to Adeno-X Viral DNA. The recombinant adenoviral plasmid was transferred to HEK293 cells by lipofectamine. After titrating the virus, the laryngeal carcinoma cells (Hep-2) were transfected by the adenovirus and the expression of EGFP gene was detected. The recombinant Ad-SP-EGFP was correctly constructed and confirmed by restriction endonuclease analysis and DNA sequencing. After Hep-2 cells were transfected by the virus, RT-PCR showed that survivin mRNA was transcribed from the tumor cells. Western blot and fluorescent microscope showed EGFP protein was expressed in transgene Hep-2 cells. Present results suggest that survivin promoter may provide a new promising tool for target gene therapy of human malignancies.  相似文献   

11.
目的 构建具有特异性瘦素(leptin)基因小于扰RNA(small interfering RNA,siRNA)功能的表达质粒,研究靶向leptin基因的siRNA对大鼠肝星状细胞(hepatic stellate cell,HSC)中leptin表达及HSC生物学特性的影响。方法 以leptin为目的基因,以产生siRNA质粒载体psiRNA-hHlneo为表达模板,细胞内转录合成4对特异的siRNA和1对对照siRNA。构建能在真核细胞中表达的重组质粒leptinsi RNA,用酶切方法和测序法对重组体进行鉴定。应用脂质体介导重组质粒转染HSC。RT-PCR、Western blot和免疫细胞化学法检测HSC的leptin表达情况,用MTT法检测细胞增殖,用流式细胞仪分析细胞凋亡。结果 酶切和序列测定表明,成功构建了leptinsiRNA表达质粒;外源重组质粒siRNA3和siRNA4能够抑制leptinm RNA和蛋白表达(均P〈0.01);HSC增殖活性显著降低(P〈0.05),凋亡增加(P〈0.01)。与未转染组相比,consiRNA、siRNA1和siRNA2转染组没有显著改变(均P〉0.05)。结论 构建的leptinsi RNA表达载体可减少leptin的表达,抑制HSC增殖并诱导其凋亡。为肝纤维化基因治疗提供了新的靶点。  相似文献   

12.
目的:构建针对衔接蛋白2的μ2亚单位(AP2-μ2)的短链干涉RNA(siRNA)及其表达载体,转染细胞后观察其对AP2-μ2基因的干涉作用。方法:设计AP2-μ2靶向的发夹状siRNA,据此设计合成3条互补的寡核苷酸链,退火后分别连接到pSilencer 3.1 neo H1载体,转化扩增后进行序列测定。待转染细胞分为对照组、Scramble plasmid、AP2 plasmid-1、AP2 plasmid-2和AP2 plasmid-3组。用脂质体转染法将3组siRNA重组质粒与阴性对照质粒(Scramble plasmid)转染大鼠心肌细胞株H9C2,通过RT-PCR法检测AP2-μ2基因表达水平的变化。结果:合成的6条寡核苷酸单链凝胶电泳显示多个电泳条带,分别退火后,产物经凝胶电泳显示形成单一条带。双链DNA模板与载体质粒连接后,用BamHⅠ和Hind Ⅲ双酶切,凝胶电泳可见4 300和66 bp的酶切片段。DNA测序连接的核酸序列与设计序列一致,表明AP2-μ2基因的3条siRNA载体构建成功。RT-PCR检测,在AP2 plasmid-1组,转染的H9C2细胞中AP2-μ2的基因表达水平较阴性对照组降低约96%。结论:成功地构建了针对AP2-μ2基因的3条siRNA载体,其中AP2 plasmid-1转染细胞后可显著抑制AP2-μ2基因表达。  相似文献   

13.
目的以PGenesil-1(Pg)为载体构建针对乙型肝炎病毒表面抗原(HBsAg)基因的shRNA表达载体PGenesil-1-HBs(Pgs)。方法设计、合成针对HBs区的三对DNA序列,分别插入PGenesil-1中,并对重组质粒进行限制性内切酶谱和DNA序列测定分析。结果3个不同的重组shRNA表达载体经限制性酶识别和DNA序列测定完全正确。结论成功构建了3个针对HBs基因的shRNA表达载体。  相似文献   

14.
目的应用载体介导的RNA干扰(RNA i)技术特异性地抑制甲状腺癌细胞人端粒酶逆转录酶(hTERT)基因的表达。方法构建利用U6启动子转录功能性小干扰RNA(siRNA)的质粒载体,对阳性克隆进行酶切和测序鉴定后,转染人甲状腺癌FRO细胞,利用RT-PCR和W eston blot法检测hTERT基因的表达情况。结果构建的表达质粒转染FRO细胞后,hTERT基因mRNA和蛋白质的表达水平明显降低,抑制率分别为76%和81%。结论siRNA的表达质粒能成功抑制甲状腺癌细胞hTERT基因的表达,为RNA i技术应用于甲状腺癌的基因治疗提供了实验基础。  相似文献   

15.
目的 构建、纯化并鉴定Rac1特异性siRNA的真核表达载体,并在HeLa细胞中初步检测其转染率及对Rac1基因的抑制率.方法 体外合成含针对人、鼠的Rac1特异基因序列的siRNA链,定向克隆至pSUPER质粒中, 对重组质粒进行限制性内切酶酶切鉴定和测序分析.将抽提的质粒转染入HeLa细胞,荧光显微镜观察转染效率,荧光定量RT-PCR法鉴定其抑制Rac1基因表达的效果.结果 利用RNAi技术成功构建抑制 Rac1 表达的小干扰 RNA 重组载体,并成功转染到HeLa细胞中(载体转染率达到70%以上).在mRNA水平对Rac1基因的表达产生明显抑制作用(抑制率为87%以上).结论 成功构建了针对Rac1的siRNA真核表达载体,为进一步研究Rac1的功能奠定了基础.  相似文献   

16.
目的:构建针对Skp2的siRNA腺病毒载体。方法:合成针对Skp2的siRNA靶DNA序列及相应阴性对照序列,退火成DNA双链,然后亚克隆穿梭质粒pShuttle-H1,Pme I线性化后,与腺病毒骨架质粒pAdeasy-1在BJ5183细菌中进行同源重组,转染AD293细胞,包装得到pAd-Skp2-siRNA和pAd-Skp2-siRNA-NC重组腺病毒。用病毒体外感染结肠癌SW480细胞,Western blot检测Skp2蛋白表达水平。结果:重组腺病毒载体经酶切、鉴定正确,制备的病毒感染效率高,能显著抑制Skp2蛋白表达。结论:细菌内同源重组成功构建了Ad-Skp2-siRNA重组腺病毒及阴性对照病毒。  相似文献   

17.
目的:构建大鼠基质金属蛋白酶抑制因子-1(TIMP-1)小干扰RNA的真核表达质粒pRNAT-U6.2 siRNA.方法: 依据siRNA设计原则确定以序列447~465 nt、522~540 nt、142~160 nt为TIMP-1 siRNA靶序列, 体外分别合成两端含BamH Ⅰ和Xho Ⅰ酶切位点的编码短发夹RNA序列的DNA单链,退火后克隆于pGEM-T载体, T7和SP6为引物进行PCR鉴定;双酶切pGEM-T将其定向克隆到siRNA表达载体pRNAT-U6.2,用pRNAT-U6.2的插入鉴定引物进行PCR鉴定,阳性重组质粒测序.结果:DNA测序证实合成的并被克隆入真核表达载体pRNAT-U6.2的siRNA插入序列与设计完全符合.结论:TIMP-1 siRNA表达载体构建成功, 为后期研究TIMP-1 pRNAT-U6.2 siRNA作用、意义及效果奠定了实验基础.  相似文献   

18.
目的:构建针对乙型肝炎病毒x基因(HBx基因)的小干扰RNA (siRNA)重组腺病毒表达载体,并在能表达HBx基因的人肝癌细胞株HepG2中观察其对HBx基因表达的抑制作用.方法:重组腺病毒穿梭载体pShuttle-HBx与骨架载体在大肠杆菌BJ5183中同源重组得到重组腺病毒载体,后者转染HEK293细胞,包装并扩增出病毒颗粒.用获得的病毒感染能表达HBx基因人肝癌细胞株HepG2,收集细胞总RNA和总蛋白,采用RT-PCR和Western Blot方法检测细胞中HBx基因表达的变化.结果:经限制性内切酶酶切鉴定,证实针对HBx基因的siRNA重组腺病毒载体构建成功.RT-PCR和Western Blot方法证实,在HepG2细胞中,HBx基因在mRNA和蛋白水平均有降低.结论:腺病毒介导的针对HBx基因的siRNA在体外能够高效、特异地抑制HBx基因的表达.  相似文献   

19.
目的 观察cubilin siRNA真核表达载体对人近端肾小管上皮细胞(human renal proximal tubular epithelial cell line,HKC)cubilin基因的特异性抑制作用.方法 针对人cubilin基因设计并构建siRNA真核表达载体pSUPER EGFP-C1和pSUPER EGFP-C2,转染HKC,经荧光定量PCR(FQ-PCR)检测cubilin mRNA的表达、不同浓度的人血清白蛋白(HSA)刺激正常HKC及转染重组质粒的HKC 24 h后cubilin mRNA的表达,并通过激光共聚焦扫描荧光显微镜观察HKC对白蛋白摄取情况的变化.结果 FQ-PCR显示HSA刺激正常HKC后cubilin mRNA表达具有剂量依赖性.与正常对照组相比,两个重组质粒均可部分抑制HKC cubilin表达,抑制效率分别为66%和37%,HSA刺激转染pSUPER EGFP-C1、pSU-PER EGFP-C2的HKC后cubiin mRNA水平较正常对照组比较分别下降50%、34%,转染了重组质粒的HKC对白蛋白的摄取明显减少.结论 成功地构建了针对人cubilin基因的RNA干扰真核表达载体,表达型siRNA可抑制肾小管上皮细胞cubilin基因的表达及对白蛋白的摄取.  相似文献   

20.
目的:构建有效针对人Dystrophin Dp71基因的短发夹RNA(short hairpin RNA,shRNA)真核表达载体,并验
证其干扰效果。方法:设计合成3对针对人Dystrophin Dp71基因的和1对无同源性的siRNA片段,在两端和中间加上酶
切位点和Loop环。将合成的DNA片段插入到干扰载体pRNAT-U6.1/Neo中,经过酶切和测序验证,成功构建人Dp71基
因的shRNA和空白对照载体。将各干扰载体和空白载体转染人正常胃黏膜上皮细胞(gastric epithelial cells,GES-1)和人
支气管上皮细胞(human bronchial epithelium,HBE),Western印迹检测Dp71 shRNA真核表达载体的干扰效率。结果:酶
切和测序验证均表明各Dp71-shRNA载体构建成功。将空载体及各Dp71 shRNA载体分别转染GES-1和HBEC,和空白细
胞对照及shRNA空白载体组相比,3组Dp71-shRNA能够明显抑制Dp71蛋白表达,但是3组质粒的抑制效率有一定的差
异,以Dp71 shRNA2对Dp71表达的干扰效率最强。结论:成功构建了3个有效针对人Dystrophin Dp71基因的shRNA 干
扰载体,3组质粒都能有效地抑制Dp71在GES-1和HBEC中的表达,其中以Dp71-shRNA2的抑制效率最高。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号